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ABSTRACT
Mutations in SQSTM1 are strongly associated with Paget’s disease of bone (PDB), but little is known about the clinical characteristics of those
with early disease. Radionuclide bone scans, biochemical markers of bone turnover, and clinical characteristics were analyzed in SQSTM1
mutation carriers who took part in the Zoledronic acid in the Prevention of Paget’s disease (ZiPP) study.We studied 222 individuals, of whom
54.9% were female, with mean SE age of 50.1  0.6 years. Twelve SQSTM1mutations were observed, including p.Pro392Leu, which was
present in 141 of 222 (63.5%) subjects. Bone scan examination revealed evidence of PDB in 20 subjects (9.0%), ten of whom (50%) had a
single affected site. Participants with lesions were older than those without lesions but the difference was not significant (53.6  9.1 versus
49.8  8.9; p = .07). The mean age of participants with lesions was not significantly different from the age at which their parents were diag-
nosed with PDB (55 years versus 59 years, p = .17). All individuals with lesions were asymptomatic. Serum concentrations of total alkaline
phosphatase (ALP) normalized to the upper limit of normal in each center were higher in those with lesions (0.75  0.69 versus
0.42  0.29 arbitary units; p < .0001). Similar findings were observed for other biochemical markers of bone turnover, but the sensitivity
of ALP and other markers in detecting lesions was poor. Asymptomatic PDB is present in about 9% of SQSTM1mutation carriers by the fifth
decade. Further follow-up of this cohort will provide important information on the natural history of early PDB and its response to treatment.
© 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
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Introduction
Paget’s disease of bone (PDB) is a skeletal disorder character-ized by focal increases in bone remodeling at one or more
sites throughout the skeleton.(1) Genetic factors play a key role
in PDB and the most important susceptibility gene is SQSTM1.(2,3)
Protein coding mutations of SQSTM1, which predominantly
affect the ubiquitin-associated (UBA) domain, have been
detected in between 40% and 50% of people with a family his-
tory of PDB and up to 15% of those who are unaware of a family
history.(4) Cross-sectional studies suggest that SQSTM1mutations
are highly penetrant such that up to 80% of carriers develop the
disease by the seventh decade.(4) Furthermore, people with PDB
that carry SQSTM1 mutations have more severe disease with an
earlier age at onset than those that do not have SQSTM1 muta-
tions.(5) Although the causal link between SQSTM1 mutations
and PDB is beyond doubt, there is limited information on the
natural history of PDB in people who carry SQSTM1 mutations
and the acceptability of genetic testing for PDB in routine clinical
practice. In order to gain an insight into these issues, we investi-
gated the clinical and biochemical characteristics of SQSTM1
mutation carriers with evidence of PDB-like bone lesions who
were enrolled into the Zoledronate in the Prevention of Paget’s
disease (ZiPP) study, which is a large-scale prospective study that
aims to investigate the acceptability of genetic testing for PDB,
coupled with offer of targeted intervention with zoledronic acid
or placebo in SQSTM1 mutation carriers.
Patients and Methods
Study design
The ZiPP study (ISRCTN Registry; http://www.isrctn.com/; Registra-
tion number: ISRCTN11616770) is a multicenter, multinational,
randomized, placebo-controlled trial involving a large scale pro-
gram of genetic testing for SQSTM1 mutations, coupled with the
offer of targeted intervention in the form of a randomized trial,
to determine whether treatment with a single infusion of intrave-
nous zoledronic acid can modify the development of PDB-related
lesions in asymptomatic carriers of SQSTM1mutations.(6) The study
commenced in 2009 and is still ongoing. The data presented here
are derived fromuntreated individualswho consented to take part
in the study and completed the baseline assessment. The ZiPP
study involved an initial phase of genetic testing for SQSTM1muta-
tions in probands known to have PDB followed by testing of first-
degree relatives (who in almost all cases were children of pro-
bands). If the relative tested positive for SQSTM1 mutations they
were then invited to participate in the ZiPP study. All individuals
gave written informed consent and the study received ethical
approval in all participating centers.
Participants
The selection process for inclusionwas broadly similar in each cen-
ter.Thelocal investigator invitedpatientswithPDBattendingoutpa-
tient clinics to undergo genetic testing for SQSTM1mutations and if
the resultwaspositive topass on the information tofirst-degree rel-
atives about the study. Relativeswho consented toundergo testing
and were found to be positive for SQSTM1 mutations were then
invited to participate in the interventional phase of the ZiPP study.
There were two exceptions; in Auckland and in Oswestry, relatives
underwent genetic testing directly without their parents having
undergone testing as part of this study. An overview of disposition
of individualswho tookpart in thegenetic testingphase is provided
in Fig. 1. We invited 2394 probands to undergo testing, and of the
1428 (59.5%) who agreed, 247 (17.2%) were found to be carriers of
SQSTM1mutations.We then invited1307 relativesof SQSTM1muta-
tion carriers to undergo testing and 750 (57.3%) agreed. Of these
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individuals, 350 (46.6%) tested positive for SQSTM1mutations and
222 (63.4%) agreed to takepart in the randomized trial. Supplemen-
taryTableS1providesfulldetailsof thenumbersofprobandsandrel-
atives screened in each study center. Participants that entered the
trial were derived from the UK (n = 134, 60.4%), Australia (n = 34,
15.3%), Italy (n = 19; 8.5%), Spain (n = 18; 8.1%), Ireland (n = 10;
4.5%), NewZealand (n=4; 1.8%), andBelgium(n=3, 1.3%). Thepar-
ticipantswere childrenof 129probandsdiagnosedwithPDB, giving
an average recruitment rate of 1.72 subjects per family.
The inclusion and exclusion criteria for participation in the trial
have been published previously, but in essence, relatives who
carried SQSTM1mutations were eligible provided that they were
age >30 years, had not been diagnosed with PDB, and had no
contraindication to receiving zoledronic acid. Recruitment to
the trial commenced in May 2009 and closed in April 2015; the
end-of-study visits are currently in progress and the results of
the study are expected to be available in 2021.
Genetic testing
Testing for SQSTM1 mutations was carried out by Sanger
sequencing of exons 7 and 8 and the intron-exon boundaries
of the SQSTM1 gene according to standard techniques. If a previ-
ously unidentified mutation was detected, bioinformatic and
functional studies were conducted to determine if it was likely
to be pathogenic.
Biochemical studies
Samples were sent for routine biochemistry at participating cen-
ters and measurements of serum creatinine (Cr), serum total
alkaline phosphatase (ALP), calcium, 25(OH)D, albumin, and liver
function, and were performed by the local chemical pathology
laboratory according to standard techniques.
Measured ALP values were adjusted to the local reference
range (RR) to give an adjusted ALP value that was used in statis-
tical analysis. The formula used for calculation was as follows:
Adjusted ALP = (measured ALP – ALP lower limit of RR)/(ALP
upper limit of RR – ALP lower limit of RR). According to this meth-
odology, a value of 1.0 would equate to an adjusted ALP at the
upper limit of the reference range, a value of 2.0 to twice the
upper limit, a value of 0.5 to the midpoint of the reference range,
and a value of 0 to the lower limit of the reference range.
Fig. 1. Recruitment into the ZiPP study. Disposition of probands and relatives of probands undergoing genetic testing for SQSTM1 mutations with the
ZiPP study population. The numbers and proportion of subjects at each stage is indicated.
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Additional markers of bone resorption and formation were
measured by enzyme-linked immunosorbent assay (ELISA)-
based techniques according to the manufacturer’s instructions
at the University of East Anglia. Crosslinked N-telopeptides of
type I collagen (NTX) were measured in urine by ELISA
(Osteomark; Ostex International, Inc., Seattle, WA, USA). The
values were corrected for Cr and were expressed in nanomoles
of bone collagen equivalents per liter (BCE; nM) per millimole
Cr per liter (mM). Interassay coefficient of variation (CV) for NTX
was ≤7.3% up to the concentration of 3000nM BCE with the
lower limit of sensitivity at 20nM BCE. The reference ranges were
5 to 65 nmol/mmol in women and 3 to 63 nmol/mmol in men.
Plasma concentrations of type I collagen C-telopeptides (CTX)
were measured using electrochemiluminesence immunoassay
(ECLIA) on a Cobas e601 analyzer (Roche Diagnostics, Mannheim,
Germany). The interassay CV for CTX was ≤3% between 0.2 and
1.5 μg/L with the sensitivity of 0.01 μg/L. The reference ranges
in women were 0.16 to 0.57 μg/L (age <50 years); 0.25 to 1.02
μg/L (age >50 years), and in men were 0.19 to 0.58 μg/L (age
30 to 50 years), 0.19 to 0.70 μg/L (age 50 to 70 years), and 0.19
to 0.85 μg/L (age >70 years). Serum bone-specific alkaline phos-
phatase (BAP) was measured using the MicroVue enzyme immu-
noassay (Quidel, Athens, OH, USA). Interassay CV for BAP was
≤2.4% up to the concentration of 140 U/L with the lower limit
of sensitivity at 0.7 U/L. The reference ranges in premenopausal
women were 11.6 to 29.6 U/L, in postmenopausal women 14.2
to 42.7 U/L, and in men 15 to 41.2 U/L. Plasma concentrations
of Procollagen type I amino-terminal propeptide (P1NP) were
measured using ECLIA on a Cobas e601 analyzer (Roche Diagnos-
tics, Mannheim, Germany). P1NP interassay CV was ≤3% between
20 to 600 μg/L with the sensitivity of 8 μg/L. The reference range in
premenopausal women was 15 to 58.6 μg/L, in postmenopausal
women 20.3 to 76.3 μg/L, and in men 20 to 76 μg/L. All samples
were collected after an overnight fast between 9:00 a.m. and
12:00 p.m., and urine samples were from the second void of
the day.
Radionuclide bone scans
Radionuclide scintigraphy was performed to detect evidence of
PDB-like bone lesions according to standard techniques in all
subjects following an injection of 99mTc-labeled bisphosphonate
at the baseline visit. Anonymized images were uploaded onto
the study database and assessed independently by two imaging
experts (DS and SHR) for evidence of PDB-like bone lesions.
Lesions were coded as being present only when they were
independently identified by both observers. The location and
number of confirmed lesions was recorded in the study data-
base. The reason for using radionuclide bone scans as the
method of assessment is that this technique is more sensitive
than plain X-rays at detecting bone lesions in PDB.(7–9) Although
many conditions can cause focal increases in tracer uptake on
bone scan, the appearances in PDB almost always allow differen-
tiation from other conditions.(10) Nonetheless, further imaging
could be performed at the discretion of the local investigator
with plain X-ray, CT, or MRI if clinically indicated or if the pattern
of uptake on the bone scan was thought not to be typical of PDB.
Statistical analysis
Descriptive and inferential statistics were generated using Mini-
tab Express version 1.5.1 (Minitab, LLC, State College, PA, USA).
Differences between groups for continuous variables were
assessed by one-way analysis of variance (ANOVA) and for cate-
gorical variables by chi-square testing. Kaplan-Meier analysis and
sensitivity and specificity testing, negative predictive (NPV), and
positive predictive values (PPV) were performed using SPSS
Table 1. Spectrum of Mutations in the ZiPP Study
SQSTM1 variant Mutations n (%) Type of mutation
p.Pro392Leu 141 (63.5) Missense
p.Gly425Arg 24 (10.8) Missense
p.Met404Val 25 (11.3) Missense
p.Gly411Ser 9 (4.1) Missense
aAla390* 8 (3.6) Truncating
p.Glu396* 3 (1.4) Truncating
p.Thr350GInfsX28 3 (1.4) Truncating
p.Phe406Val 2 (0.9) Truncating
p.Lys378* 2 (0.9) Truncating
p.Gln371* 2 (0.9) Truncating
p.Ile424Ser 2 (0.9) Missense
p.Glu396* 1 (0.46) Truncating
Table 2. Characteristics of Participants With andWithout Lesions
Variable
Lesion
(n = 20)
No lesion
(n = 202) p
Age (years), mean  SD 53.6  9.1 49.8  9.0 .07
Gender .95
Male, n (%) 10 (50.0) 90 (44.5)
Female, n (%) 10 (50.0) 112 (55.4)
Serum calcium
(mmol/L), mean  SD
2.41  0.16 2.40  0.11 .63
Serum 25(OH)D
(nmol/L), mean  SD
50.1  26.2 52.2  29.7 .76
Adjusted ALP (AU),
mean  SD
0.75  0.69 0.42  0.29 <.0001
Elevated ALP, n (%) 4/20 (20.0) 16/198 (8.0) .007
uNTX/Cr (nM/mM),
mean  SD
305.5  808.6 51.9  51.9 <.0001
Elevated uNTX/Cr, n (%) 10/15 (66.6) 5/132 (3.8) .0075
BAP (U/L), mean  SD 15.1  12.8 10.4  7.0 .015
Elevated BAP, n (%) 1/17 (5.8) 1/186 (0.5) .16
CTX (μg/L), mean  SD 0.44  0.26 0.32  0.15 .004
Elevated CTX, n (%) 2/17 (11.7) 15/187 (8.0) .17
P1NP (μg/L), mean SD 99.9  84.9 53.4  22.3 <.0001
Elevated P1NP, n (%) 10/17 (58.8) 35/187 (19.2) .0001
Mutation type, n (%) 1.0
Missense 19 (94.4) 184 (91.0)
Truncating 1 (5.6) 18 (8.9)
Sites affected, n (%)
1 10 (50.0) –
2 6 (30.0) –
≥3 4 (20.0) –
Values are mean  SD or numbers and percentages. The p values refer
to differences between groups assessed by t test for continuous variables
or Fisher’s exact test for categorical variables. Serum calcium values were
adjusted for albumin.
ALP = total alkaline phosphatase; AU = arbitary units; BAP = bone-specific
alkaline phosphatase; CTX = C-terminal collagen crosslinks; P1NP = procolla-
gen type-I N-terminal propeptide fragment; uNTX/Cr = urinary
N-telopeptide collagen crosslinks/urine creatinine.
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version 24 (IBM Corp., Armonk, NY, USA). The significance level
was set at p < .05 and all tests were two-tailed.
Results
Clinical characteristics, demographics and spectrum of
SQSTM1 mutations
Of the 222 SQSTM1 positive individuals enrolled into the study,
122 (54.9%) were female. The mean  SD age participants was
50.2  9.1 years. The demographics of these subjects were similar
to the 128 relatives who tested positive and who decided not to
enroll in the study. The average age of these individuals was
53.1  13.3 years and 79 (61.7%) were female. The spectrum of
mutations in subjects who were enrolled into the trial is shown
in Table 1. Twelve mutations were identified, the most common
of which was p.Pro392Leu, along with a variety of other missense
and truncation mutations that have all been previously reported.
The average adjusted ALP value was 0.44  0.35, and in 20 of
222 individuals (9.0%) the ALP was above the upper limit of the
local reference range. None of the participants had symptoms or
signs of PDB at the time of recruitment or the baseline visit.
The characteristics of participants with lesions compared to
those without lesions are shown in Table 2. The most commonly
involved anatomical sites were the pelvis and spine. Most partic-
ipants with lesions had monostotic disease (10/20; 50%). Repre-
sentative examples of lesions are shown in Fig. 2A-D.
Participants with lesions were on average about 5 years older
than those without lesions but this difference was not significant
(p = .07). Lesions were equally common in men and women.
There was no difference in the proportion of subjects with
lesions depending on whether the mutation was missense or
truncating. All of the biochemical markers of bone turnover
tested were significantly higher in those with lesions as com-
pared with those who did not have lesions (Table 2). The sensitiv-
ity of ALP and other biochemical markers in detecting individuals
lesions was generally poor, although specificity was above 80%
for all of the markers except urinary NTX (uNTX)/Cr (Table 3).
Fig. 2. Representative images from participants with bone lesions. (A)
Radionuclide bone scan image showing intense tracer uptake in cervical
vertebrae 4 and 5. (B) Radiograph from the same patient showing typical
features of Paget’s disease with expansion and fusion of C4 and C5. The
patient was asymptomatic and had no neurological abnormalites. (C)
Radionuclide bone scan image showing increased tracer uptake in the
upper femur on the left side. (D) Radiograph from the same patient show-
ing coarsening of the trabecular pattern in the upper femur and cortical
thickening of the medial aspect of the upper femur.
Table 3. Predictive Values of Biochemical Markers in Detecting Individuals With Lesions
Biomarker Sample Units Sensitivity (%) Specificity (%) PPV (%) NPV (%) Samples (N)
ALP Serum AU 20.0 97.0 40.0 92.4 222
uNTX/Cr Urine nM/mM 66.7 67.5 14.1 96.2 203
CTX Plasma ug/L 11.7 92.3 22.2 92.3 204
P1NP Plasma ug/L 58.8 81.3 22.2 95.6 204
BAP Serum U/L 5.9 99.4 50.0 92.0 203
ALP = total alkaline phosphatase; AU = arbitary units; BAP = bone-specific alkaline phosphatase; CTX = C-terminal collagen crosslinks; N = number of
samples where results were available; NPV = negative predictive value; P1NP = procollagen type-I N-terminal propeptide fragment; PPV = positive pre-
dictive value; uNTX/Cr = urinary N-telopeptide collagen cross links/urine creatinine.
Fig. 3. Comparison of age at diagnosis in probands with Paget’s disease
and their children. The age at clinical diagnosis of Paget’s disease in pro-
bands is compared with the age at which their children were diagnosed
with Paget’s disease through radionuclide bone scan imaging in the ZiPP
study.
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Information on age at clinical diagnosis of PDB in the pro-
bands was available for 12 of the subjects with bone lesions.
Kaplan-Meier analysis showed that the estimated mean age at
clinical diagnosis in probands was 57.3 years (95% CI, 52.9 to
61.6) as compared with 53.6 years (95% CI, 49.6 to 57.6) for the
children who had PDB lesions on bone scan, a difference that
was not significant (p = .17) (Fig. 3).
Discussion
Genetic factors play a key role in the pathogenesis of PDB, and it
has previously been suggested that genetic testing for SQSTM1
mutations and other susceptibility alleles might be used clini-
cally to detect people with the disease.(11) The ZiPP study is
unique in that it comprised a large-scale program of genetic test-
ing for SQSTM1 mutations in both probands and relatives,
coupled with the offer of targeted intervention to prevent the
development of PDB in relatives that tested positive. To our
knowledge the acceptability of genetic testing for susceptibility
to PDB has not previously been explored in this way. Our study
showed that uptake of the offer of genetic testing was reason-
ably good in both probands (59%) and relatives (57%), indicating
that this approach is acceptable to the target population and
could be implemented in clinical practice in the future, should
the ZiPP study show evidence of benefit of zoledronic acid in
slowing or preventing the emergence of PDB in this high risk
group.
Analysis of the baseline data confirmed the relevance of
SQSTM1 mutations as a risk factor for PDB reflected by the fact
that 20 of 222 (9.0%) of participants in the study already had evi-
dence of early PDB on bone scan at the baseline visit. In most
cases, the imaging findings were consistent with mild disease
but one individual had already developed a striking deformity
of two cervical vertebrae at the time of enrolment into the study
(Fig. 2B). Interestingly, this participant, in common with other
participants, had not experienced symptoms related to PDB.
Measurements of ALP were performed in all subjects at the
baseline visit along with other markers of bone turnover. All bio-
chemical markers of bone turnover that we measured were sig-
nificantly higher in people with lesions as compared with those
without lesions but the sensitivity of these markers in detecting
people with lesions was poor. Although previous studies have
shown that markers such as ALP, BAP, and P1NP are elevated
in a high proportion of individuals with established PDB, most
of the participants in this study had very early disease, which
could explain why only a modest proportion of people with
lesions had elevated marker levels. Whatever the reason it is
clear that screening with biomarkers is not an effective method
of detecting lesions in SQSTM1 mutation carriers.
Our findings are of interest in relation to the previous study by
Bolland and colleagues(12) and Cundy and colleagues,(13) who
screenedforevidenceofPDBbyscintigraphy inthechildrenof indi-
viduals from10kindredswithfamilialPDBcausedbySQSTM1muta-
tions. In their initial study four of 23 (17%) offspring with SQSTM1
mutationshadevidenceofPDBonbonescintigraphyatanaverage
age of 45 years.(12) Subsequent follow up of this cohort 5 years
later(13) revealed the emergence of PDB in two carriers who did
not have evidence of the disease at baseline. Another study by
Peeters and colleagues(14) evaluated 14 SQSTM1mutation carriers
from the Netherlands who were followed for periods of up to
15 years. The design of this study differed from that reported here
because scintigrams were only performed in participants who
had raised levels of ALP or P1NP or both. Of the eight subjects
who underwent scintigraphy, new onset PDB was identified in
one case (12.5%). The data presented here show that PDB lesions
can be present on scintigraphy even though ALP and P1NP values
are normal and so it is possible some of the subjects studied by
Peeters andcolleagues(14)whodidnot undergo scintigraphy could
have had occult lesions in the absence of biochemical
abnormalities.
In contrast to thefindings reportedbyBollandandcolleagues(12)
and Cundy and colleagues(13) who used similar methodology to
that reported here, we did not observe a delayed onset of PDB in
the childrenof patientswhohad SQSTM1mutations. It is important
to point out, however, that in this study and previous studies, indi-
viduals were actively screened for PDB by radionuclide bone scan-
ning,andit isquite likely that severalyearsmayhaveelapsedbefore
the diagnosismay have been picked up in routine clinical care. We
think that the lowerproportionof individualswith lesionsobserved
in this study as compared with Bolland and colleagues’ study(12)
was that we enrolled individuals who tested positive for SQSTM1
mutations irrespective of whether other family members were
affected,whereas Bolland and colleagues(12) focused exclusively
on nuclear families with SQSTM1mutations.
The present study attests to the fact that PDB is a clinically
silent condition in the early stages and may remain so for many
years. This is in keeping with the findings of another study which
revealed that in about 40% of individuals, PDB first presents with
a complication of the disease such as deformity, fracture, or deaf-
ness.(15) Although nitrogen-containing bisphosphonates are
highly effective at supressing elevated bone turnover in
PDB(16,17) and are effective at treating bone pain associated with
PDB,(18,19) the PRISM and PRISM-EZ trials showed that long-term
supression of bone turnover with bisphosphonates carried no
advantage over symptom-directed treatment in preventing
complications of PDB such as progression of deafnes, osteoar-
thritis, quality of life, or pathological fractures.(20,21) The results
of these studies provided the impetus for undertaking the ZiPP
trial, which seeks to determine if intervening at a very early stage
may favorably alter the natural history of the disease.
The ZiPP study has confirmed the importance of SQSTM1
mutations as a genetic risk factor for PDB and has shown that a
programme of genetic testing coupled to therapeutic interven-
tion is both acceptable and feasible in the target population.
Given that most participants with lesions had early-stage dis-
ease, it is likely that longer-term follow-up of this cohort will be
required to further investigate the effects of the intervention
on symptoms and complications. This is being achieved through
the ZiPP–long-term extension (ZiPP-LTE) study (NCT03859895),
in which participants who completed ZiPP will be offered follow
up for a further 5 years.
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